Pfizer
NEWS
Despite Political Rhetoric, Some Drug Prices Jumped on July 1, Including Medicines on Shortage Lists
The beginning of July is when many companies increase the price on prescription medications in the U.S. This year’s price increases are higher than the same period last year.
Pfizer Reports Failure in Persistent Pulmonary Hypertension, Progress in Duchenne Muscular Dystrophy
Pfizer’s intravenous (IV) Revatio (sildenafil), when added to inhaled nitric oxide (iNO), failed to meet its primary efficacy endpoint in treating newborns with Persistent Pulmonary Hypertension (PPHN).
Gottlieb’s knowledge of the regulatory and political landscape will be a boon for Pfizer as it dives deeper into oncology.
The public’s perception of the drug industry can be confusing. Recent studies take a hard look at the industry from different perspectives.
Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
The patients receiving Lyrica didn’t show a statistically significant reduction in seizure frequency compared to placebo.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
The FDA approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) as the first treatments for transthyretin-meditated amyloidosis.
JOBS
IN THE PRESS